India's greenfield bulk drugs drive amidst shift from China
The Indian pharmaceutical sector is poised for a substantial makeover with the inauguration of 27 greenfield plants dedicated to manufacturing bulk drugs. These plants signify a pivotal shift in India's pharmaceutical landscape and an in-your-face statement to the heavy import dependence on China, reports The Pharma Letter’s India correspondent.
The government's approach to the COVID-19 pandemic was an opportunity for transformation, said Rajesh Kumar Singh, from the Department for Promotion of Industry and Internal Trade. Underscoring the administration's commitment to bolstering self-reliance, fostering innovation, and enhancing infrastructure, Mr Singh said the Production Linked Incentive (PLI) scheme was conceived to promote localization and value addition within India's pharmaceutical and MedTech sector,
Speaking at an event, Mr Singh said it aims to mitigate over-dependence on critical resources from specific geographic regions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze